» Articles » PMID: 15962005

Intravenous Apoptotic Spleen Cell Infusion Induces a TGF-beta-dependent Regulatory T-cell Expansion

Overview
Specialty Cell Biology
Date 2005 Jun 18
PMID 15962005
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Apoptotic leukocytes are endowed with immunomodulatory properties that can be used to enhance hematopoietic engraftment and prevent graft-versus-host disease (GvHD). This apoptotic cell-induced tolerogenic effect is mediated by host macrophages and not recipient dendritic cells or donor phagocytes present in the bone marrow graft as evidenced by selective cell depletion and trafficking experiments. Furthermore, apoptotic cell infusion is associated with TGF-beta-dependent donor CD4+CD25+ T-cell expansion. Such cells have a regulatory phenotype (CD62L(high) and intracellular CTLA-4+), express high levels of forkhead-box transcription factor p3 (Foxp3) mRNA and exert ex vivo suppressive activity through a cell-to-cell contact mechanism. In vivo CD25 depletion after apoptotic cell infusion prevents the apoptotic cell-induced beneficial effects on engraftment and GvHD occurrence. This highlights the role of regulatory T cells in the tolerogenic effect of apoptotic cell infusion. This novel association between apoptosis and regulatory T-cell expansion may also contribute to preventing deleterious autoimmune responses during normal turnover.

Citing Articles

Efferocytosis: The Janus-Faced Gatekeeper of Aging and Tumor Fate.

Liu Z, Li Y, Ren Y, Chen J, Weng S, Zhou Z Aging Cell. 2025; 24(2):e14467.

PMID: 39748782 PMC: 11822654. DOI: 10.1111/acel.14467.


Microparticles incorporating dual apoptotic factors to inhibit inflammatory effects in macrophages.

Simpson S, Middleton D, Lukesh N, Islam M, Ehrenzeller S, Bachelder E J Pharm Sci. 2024; 113(11):3196-3205.

PMID: 38852674 PMC: 11560629. DOI: 10.1016/j.xphs.2024.05.030.


Engineering Efferocytosis-Mimicking Nanovesicles to Regulate Joint Anti-Inflammation and Peripheral Immunosuppression for Rheumatoid Arthritis Therapy.

Yuan S, Chai Y, Xu J, Wang Y, Jiang L, Lu N Adv Sci (Weinh). 2024; 11(28):e2404198.

PMID: 38810118 PMC: 11267389. DOI: 10.1002/advs.202404198.


Safety of Repeated Administration of Xenogeneic Human Apoptotic State (Allocetra-OTS) in Sprague Dawley Rats.

Ankri C, Hershkovitz O, Hershkovitz L, Brami M, Levy R, Sarig H Pharmaceutics. 2024; 16(3).

PMID: 38543320 PMC: 10975356. DOI: 10.3390/pharmaceutics16030426.


Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy.

Han H, Wang L, Ding Y, Neuber B, Huckelhoven-Krauss A, Lin M Blood Adv. 2024; 8(11):2675-2690.

PMID: 38359409 PMC: 11170151. DOI: 10.1182/bloodadvances.2023012463.


References
1.
Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

2.
Albert M . Death-defying immunity: do apoptotic cells influence antigen processing and presentation?. Nat Rev Immunol. 2004; 4(3):223-31. DOI: 10.1038/nri11308. View

3.
Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M . Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004; 172(9):5149-53. DOI: 10.4049/jimmunol.172.9.5149. View

4.
Apostolou I, von Boehmer H . In vivo instruction of suppressor commitment in naive T cells. J Exp Med. 2004; 199(10):1401-8. PMC: 2211808. DOI: 10.1084/jem.20040249. View

5.
Perruche S, Kleinclauss F, Bittencourt M, Paris D, Tiberghien P, Saas P . Intravenous infusion of apoptotic cells simultaneously with allogeneic hematopoietic grafts alters anti-donor humoral immune responses. Am J Transplant. 2004; 4(8):1361-5. DOI: 10.1111/j.1600-6143.2004.00509.x. View